¸õ¨ì¥D­n¤º®e°Ï¶ô

»O¤jÂå°|®È¹CÂå¾Ç±Ð¨|°V½m¤¤¤ß

MENU
  • ²L½Í°ª¤s¯g

 

                                 ½Ã¥Í¸p¥ß°ò¶©Âå°|  ®a®xÂå¾Ç¬ì  ³¯¬f¼ý

 

¡@¡@ÀHµÛ²{¥N¤Æ¥æ³q¤u¨ãªº¶i¨B¡A¥H¤Î¥@¤H®È¹C¼Ð²`«×»P¼s«×ªº¼W¥[¡A°ª¤s¯g(altitude illness) ¦¨¬°®È¹CÂå¾Ç¤¤¤@­Ó«D±`­«­nªº½ÒÃD¡C¥@¬É³Ì°ªªº¾÷³õ¦ì¦b¬Á§Qºû¨È­º³£©Ô¤Ú´µ(La Paz)¡A®ü©Þ3,819¤½¤Ø¡A¾÷³õ§YÀH³B³Æ¦³®ñ®ð²~¡F¨j³q¨®¤T¦~ªº«CÂÃÅK¸ô®æº¸¤ì¦Ü©ÔÂĬq¡A¬°¥@¬É¤W³Ì°ª®ü©ÞªºÅK¸ô¡A³Ì°ªÂI¦ì©ó®ü©Þ5,072¤½¤Øªº­ð¥j©Ô¤s¤f¡A§Y¨Ï¦³¥[À£¿µ³]­p©M¨Ñ®ñ³]³Æ¡A¤´°¸¦³¶Ç¥X®È«ÈÄY­«°ª¤s¯g¦º¤`ªº®×¨Ò¡C

¡@¡@¦b¥xÆW¡A³\¦h°ª¤s­·´º°Ï¤w¹F®e©öµo¥Í°ª¤s¯gªº®ü©Þ°ª«×¡C¥H¤½¸ô©ö¹F©Ê°ªªº¦XÅw¤s¬°¨Ò¡A¦ÜÂåÀø¯¸¨D¶Eªº¹C«È¤¤¶W¹L¤@¥b¬O°ª¤s¯g¡C¤@¯ëµn¥É¤s¥D®pªº¦æµ{¡A¬ù¦³¤K¦¨µn¤s«È·|¥X²{¦Ü¤Ö¤@¶µ°ª¤s¯gª¬¡Cªñ¼Æ¤Q¦~¨Ó¡A°ª¤s¦Ê©¨Ãkª¦­·®ð²±¦æ¡AµM¨C¦~§¡·|µo¥Í¦h°_¦]°ª¤s¯g¨D´©¬Æ¦Ü¦º¤`ªº®×¨Ò¡A³o¨ÇÄY­«ªº°ª¤s¯g¦h¼Æ»F¦]©ó¹ï°ª¤s¯gªº»{ª¾¤£¨¬¡B¦æµ{¦w±Æ©ÎÁ{³õ³B¸m¥¢·í¡A¬O¥i¥HÁקKªº¡C

¡@¡@Âå¬É¹ï©ó°ª¤s¯gªº»{ÃÑ¡A¯S§O¬O¦b®È¹CÂå¾Ç©Î®a®xÂå¾Ç¬ìªù¶E¡A¹ï©ó¹w³Æ°ª®ü©Þ®È¦æªÌªº¹w¨¾©Ê«Øij¡A¦³§U©ó´î¤Ö¦]°ª¤s¯g»´«h´î§C¹C¿³¡B­««h³à©Rªº´d¼@µo¥Í¡C

 

°ª®ü©Þ¬¡°Ê¹ï¥Í²zªº¼vÅT

 

¡@¡@ÀHµÛ®ü©Þ°ª«×º¥¤É¡A¤j®ðÀ£¤O©M®ñ®ð¤ÀÀ£¤]ÀH¤§­°§C¡C¦b®ü©Þ3,000¤½¤Ø°ª³B¡A®ñ®ð¤ÀÀ£¬ù¬°®ü¥­­±ªº70%¡A®ü©Þ4,000¤½¤Ø³B¬ù¬°61%¡A®ü©Þ5,000¤½¤Ø³B«h­°¬°53%¡C

¡@¡@¦b°ª®ü©Þ¬¡°Ê¡A¨­Å鬰¤F¯à¾AÀ³¯Ê®ñªºÀô¹Ò¡Aºû«ù¥¿±`¥Í²z¾÷¯à¡A°µ¤F³\¦h§ïÅÜ¡A¥]¬A¤ß¿é¥X¶q¼W¥[¡B¦å¤ñ®e¼W¥[¡B¬õ¦å²y¼W¥Í¡BÅé°Ê¯ßÂX±i¥H¼W¶i¦Ù¦×¤Î¸£³¡¦å¬y¶q¡BªÍ¤p°Ê¯ß¦¬ÁY¥H¦]À³¯Ê®ñª¬ºA¡BªÍ°Ê¯ßÀ£¼W¥[¡C

¡@¡@¥Ñ©ó¹B°Ê²£¥Í¤j¶q¤G®ñ¤ÆºÒ¡BpH­È­°§C¡A©MÀV°Ê¯ßÄu°»´ú¨ì¯Ê®ñ¡A¤GªÌ¦@¦P¨ë¿E©µ¸£ªº©I§l¤¤¼Ï¥[§Ö¥[²`©I§l¡AºÙ¬°¯Ê®ñ´«®ð¤ÏÀ³(hypoxic ventilatory response)¡C¦¹®É¡A¤G®ñ¤ÆºÒ¥[§Ö±Æ¥X¦³§U©ó´£°ªªÍªw¤ºªº®ñ®ð¤ÀÀ£(PAO2)¡AµM¦Ó«o¨Ï¦å²G°¾ÆP¡A¤£§Q©óºû«ù°ª³q®ð¶q¡CµÇŦ·|¸g¥Ñ§âºÒ»Ä²B®Ú±Æªn¨ì§¿²G¤¤¡AÁB¥¿ÆP¦å¯g¡A¨Ï±o¸£¯á²G¤¤ºÒ»Ä²B®Ú³vº¥­°§C¡A±j¤Æ¤G®ñ¤ÆºÒ¿@«×©M»Ä©Ê¹ï©ó©I§l¤¤¼Ïªº¨ë¿E¤ÏÀ³¡C³o¾ã­Ó¹Lµ{ºÙ¤§¬°°ª«×¾AÀ³(acclimatization)¡C

¡@¡@¤HÅéªÍªw¤ºªº®ñ®ð¤ÀÀ£(PAO2)«h»P±Æ¥Xªº¤G®ñ¤ÆºÒ¤ÀÀ£¡Ð¥ç§Y°Ê¯ß¦å¤G®ñ¤ÆºÒ¤ÀÀ£(PaCO2)¬ÛÃö¡APaCO2¶V§C«hPAO2¶V°ª¡G

PAO2 = (Patm - PH2O) * FiO2 - (PaCO2 / Q)      Q¡G©I§l°Ó

¡C°ª«×¾AÀ³ªºµ²ªG¼W¥[³q®ð¶q¡A¦³§U©ó­°§CPaCO2¥H´£¤ÉPAO2¡C

¡@¡@¥t¤@¤è­±¡APAO2ªº¤U­°»PªÍªw·L¦åºÞ¤¤ªº¦å¬õ¯À§t®ñ¹¡©M«×¡]¬ùªñ¦ü©ó°Ê¯ß¦å®ñ¹¡©M«×¡ASaO2¡^¤§¶¡ªºÃö«Y¤£¬O½u©Êªº¡A¨ú¨M©ó¤U¦C¦]¯À¡G

  1. ªÍªw³q®ð¶q©M·L¦åºÞÄé¬y¶q°t¦X¤£¨}(ventilation-perfussion mismatch)¡A¾É¦]©óªÍ³¡ªº¦ºµÄ©M¤À¬y¡CªÍ¤p°Ê¯ß­ì¦³¦]À³³q®ð¤£¨¬ªº¦Û§Ú½Õ¸`¥\¯à¡AµM¦Ó¦b¯Ê®ñª¬ºA¤U¡AªÍ¤p°Ê¯ß¥þ­±©Ê¦¬ÁY±N³y¦¨ªÍ°Ê¯ßÀ£¤O¼W¥[¡C­YªÍ¤p°Ê¯ß¦¬ÁY¤£¥­§¡¡A·|¾É­P³¡¥÷·L¦åºÞ·¸¥X¤ô¥÷¦Ó³y¦¨ªÍ¤ô¸~¡C
  2. ªÍªwµÄ©MªÍªw·L¦åºÞªº®ñ®ð¤ÀÀ£¥HÂX´²§@¥Î¹F¨ì¥­¿Å»Ý­n¨¬°÷ªº®É¶¡¡CPAO2¶V§C¡AªÍªwµÄ©MªÍªw·L¦åºÞ/°Ê¯ß¦å®ñ¤ÀÀ£®t¶Z(A-a gradient)¶V¤p¡AÂX´²§@¥Î¶VºC¡A¥[¤W¹B°Ê®É¡A¤ß¿é¥X¶q¼W¥[¥H­P¦å¬y¥[³t¡A¬õ¦å²y¬y¸gªÍªw·L¦åºÞ©Ò»Ý®É¶¡©úÅãÁYµu¡A¬Ò¾É­PªÍªw·L¦åºÞ¨Ó¤£¤Î»PªÍªwµÄ¹F¦¨®ñ®ð¤ÀÀ£¥­¿Å¡APaO2­°§C¡C
  3. ®ñ®ð-¦å¬õ¯À¸ÑÂ÷¦±½u(O2-Hb dissociation curve)ªº§@¥Î¡C·íPaO2¦b80mmHg¥H¤W¡A°Ê¯ß¦å®ñ¹¡©M«×(SaO2)¥iºû«ù¦b95.8%¥H¤W¡AµM¦Ó·íPaO2¶i¤@¨B¤U­°®É¡ASaO2§Y§Ö³t¤U­°¡A¥H­P©ó¤HÅ饲¶·¶i¤@¨Bªº½Õ¾ã¥HÀ³¹ï¯Ê®ñª¬ºA¡C¸û°ªªº·Å«×©M¸û§CªºpH­È·|¨Ï¦¹¦±½u¦V¥k²¾°Ê¡A¦å¬õ¯À»P®ñ®ðµ²¦X¤OÅÜ®z¡ASaO2­°§C¡C¦b°ª®ü©Þ®É¡A¥NÀv©Ê´«®ð¼W¥[¨ÏPaCO2´î¤Ö¡A¶i¦Ó´£°ªpH­È¡A®ñ®ð-¦å¬õ¯À¸ÑÂ÷¦±½u¦V¥ª°¾²¾¡A¦³§U©ó´£°ªªÍªw·L¦åºÞ»PÅé°Ê¯ß¦å®ñ¹¡©M«×¡C

¡@¡@¦b®ü©Þ1,500¤½¤Ø³B¡A¤ßªÍ¥\¯à¥¿±`ªº¤HSaO2¬ù¦b95%¥ª¥k¡C¦¹®ü©Þ¥H¤W§Y¬°¥Í²z¤Wªº°ª®ü©Þ¡A¤]¬O°£«D¦³¯S®í¯e¯f(¤ñ¦p­ìµo©Î¦¸µo©ÊªÍ°Ê¯ß°ªÀ£¡B©ÎºC©Êªý¶ë©ÊªÍ¯f)¡A°·±d¤HÃþ·|¥X²{°ª¤s¯gªº³Ì§C®ü©Þ¡AÁöµM³q±`µo¥Í¦b2,100~2,500¤½¤Ø¤W¥Hªº®ü©Þ¡C¦b®ü©Þ5,500¤½¤Ø³B¡A§Y¨Ï¸g¹L¥R¥÷°ª«×¾AÀ³¡AªÍªw¥­¿Å«áªºSaO2¬ù¥u¦³75%¡A­Yªø´Á©~¯d¶Õ¥²·|µo¥Í¶i¦æ©Ê°IºÜ(altitude deterioration)¡A²×¦ÜµLªk¦s¬¡¡A¦¹°ª«×¬O©Ò¿×·¥«×°ª®ü©Þ(extreme high altitude)¡C

 

°ª¤s¯gªº¦nµo¦]¤l»P¼ç¦b¯e¯f¤§ÃöÁp

 

¡@¡@¨C­Ó¤H¹ï©ó°ª¤s¯gªº©ö·P¨ü©Ê³£¤£¦P¡A¤]¨S¦³¨}¦nªº¿z¿ï¤u¨ã¥i¥H¹w´ú­Ó¤H°ª¤s¯gªºµo¥Í¡C³oºØÅé½è©Êªº®t²§¸ò¥­¦aªºÅé¯àªí²{©M°V½mµLÃö¡A¦ýµo¥Í¹L°ª¤s¯gªº¤H¦A«×µo¥Íªº¾÷²v¤j¬°´£°ª¡Cªø´Á©~¦í¦b°ª®ü©Þªº©~¥Á¤ñ¸û¯à¾AÀ³§ó°ª®ü©ÞªºÀô¹Ò¡AµM¦ÓºC©Ê°ª¤s¯g·|±a¨Ó¥t¤@¨Ç°·±d¤Wªº­·ÀI¡C¬Y¨Ç¬ã¨s«ü¥X¤­¤Q·³¥H«á¥Ñ©ó¤j¸£µäÁY¡A°ª¤s¯gªºµo¥Í²vÀH¤§­°§C¡C¨k©Ê¦b°ª®ü©ÞªÍ¤ô¸~ªºµo¥Í²v¦ü¥G²¤°ª©ó¤k©Ê¡A¦ý³oºØ®t²§¨Ã¤£¬O«Ü©úÅã¡C

¡@¡@©]¶¡¶g´Á©Ê©I§l»F¦]©ó¯Ê®ñª¬ºA¤U¤G®ñ¤ÆºÒ»P»Ä«×¹ï©I§l¤¤¼Ïªº­t¦^õX¤ÏÀ³¡A·|¾É­P°Ê¯ß¦å®ñ¹¡©M«×­°§C¡AµM¦Ó¨S¦³©ú½TªºÃÒ¾Ú¤ä«ù¶g´Á©Ê©I§l»P°ª¤s¯gªºµo¥Í¬ÛÃöÁp¡AÁöµM¥¦ªº½T·|´c¤Æ¤wµo¥Íªº°ª¤s¯g¯gª¬¡C

¡@¡@­ìµo©Î¦¸µo©ÊªÍ°Ê¯ß°ªÀ£¡B¤ß©ÎªÍ¤º¤À¬y¤ÎºC©Êªý¶ë©ÊªÍ¯f¡A¬O¼ç¦b¯e¯f¤¤³Ì®e©ö»¤µo¤Î´c¤Æ°ª¤s¯g¯gª¬ªº¡C¦³¥ô¦óªÍ¯e¯f¡BÆ{¦å©Ê¤ß°IºÜ¡B¤ß¦Ù±ð¶ë©Î¤£Ã­©w¤ßµ±µh±wªÌ©y©ó°ª®ü©Þ®È¹C«e¦V­ì¶EªvÂå®v©Î®È¹CÂå¾Çªù¶EÂå®v¿Ô¸ß¬O§_»Ý­n­­¨îµn°ª¡C¿}§¿¯f¯f±w¡A¯S§O¬O¦å¿}±±¨î¤£¨ÎªÌ¡A¦b°ª®ü©Þ·|¼W¥[଻Ĥ¤¬r©Mµøºô½¤¥X¦åªº­·ÀI¡C®ð³Ý¡B°ª¦åÀ£©M±±¨î¨}¦nªº«aª¬°Ê¯ß¯e¯f±wªÌ¨Ã¤£·|¦]°ª®ü©Þ®È¦æ¦Ó¨Ï±o­ì¦³¯e¯f´c¤Æ¡A©Î¼W¥[°ª¤s¯gªºµo¥Í¡C

 

°ª¤s¯gªºÁ{§É¯gª¬»P¶EÂ_

 

¡@¡@°ª¤s¯g¬O¤@³s¦ê¯e¯f¹êÅ骺Á`ºÙ¡A¥]¬A«æ©Ê°ª¤s¯f(acute mountain sickness, AMS)¡B°ª®ü©Þ¸£¤ô¸~(high altitude cerebral edema, HACE)¡B°ª®ü©ÞªÍ¤ô¸~(high altitude pulmonary edema, HAPE)¡B·¥ºÝ°ª®ü©Þªº¶i¦æ©Ê°IºÜ(altitude deterioration)¡BºC©Ê°ª¤s¯f(chronic mountain sickness)¡C¥Ø«e³Ì³QÃöª`ªº°ª®ü©Þ¯e¯f¬°«e¤TªÌ¡A¨ä¤¤AMS³Qµø¬°HACEªº«eÅX¯e¯f¡A¾Ö¦³¦@¦Pªº­P¯f¾÷Âà¡Aµo¥ÍHACE¤§«e´X¥G³£¦³AMSªº¯gª¬¥X²{¡CHAPE«h¥i¥H¦b¨S¦³AMSªº±¡ªp¤U³æ¿Wµo¥Í¡C

¡@¡@°ª¤s¯gª¬ªºªí²{¦h¼Ë¡Aªì´Á³q±`¤£¨ã¯S²§©Ê¡A¨Ò¦pÀYµh¡BÀY·w¡Bäú¤ß¡B¹½­¹¡Bµê®z¡B¥¢¯v¡C´c¤Æ¤¤ªºAMS¡A©Î¤w¸g²£¥ÍHACE¡BHAPEªº±wªÌ¡A«h·|¥X²{·NÃѧïÅÜ¡B¨BºA¤£Ã­¡B«y¹Â¡B¥ð®§ª¬ºA¤U©I§l§xÃø¡B¬¡°Ê¤O´î§C¡B¯Ý´e¤Î«y¦åµ¥¯gª¬¡CŲ©óÄY­«°ª¤s¯gªº¹w¨¾¡A¦³·sªñªº®ü©Þª¦ª@¡A¥X²{¥ô¦óµLªk¤À¿ëªº¤£¾A¯gª¬³£À³°²³]¬O¿©±w°ª¤s¯g¨ÃÄY¥[Æ[¹î¡B¸T¤î¤W¤É°ª«×¡Aª½¨ì©úÅãÃҹꤣ¬O°ª¤s¯g¬°¦¹¡C

¡@¡@®Ú¾ÚLake Louise Consensus¡A°ª¤s¯gªº¶EÂ_¼Ð·Ç¦p¤U¡G

ùþ «æ©Ê°ª¤s¯f(acute mountain sickness, AMS)

¡@ ·sªñ¦³®ü©Þª¦¤É¡A¥²¶·¦³ÀYµh¥[¤W¤U¦C¯gª¬¦Ü¤Ö¨ä¤¤¤§¤@¡G

¡@¡@1. ¸z­G¤£¾A¡]­¹¼¤¤£®¶¡Bäú¤ß©Î¹Ã¦R¡^

¡@¡@2. ¯h¾Î©Î°I®z

¡@¡@3. ÀY·w©ÎÀY©ü

¡@¡@4. ¤JºÎ§xÃø

¡@¡@ùþ °ª®ü©Þ¸£¤ô¸~(high altitude cerebral edema, HACE)

¡@¡@¡@ ·sªñ¦³®ü©Þª¦¤É, ¥B¦³¤U¦C¤GªÌ¤§¤@ªº±¡ªp¡G

  1. ¨ãAMS¯gª¬¡A¦P®É¨BºA¤£Ã­©Î·NÃѧïÅÜ¡C

¨BºA¤@¯ë¥HTandem gait¬°´ú¸Õ¼Ð·Ç¡C

        2. ¨BºA¤£Ã­¦Ó¥B·NÃÑÅܤơA¤£ºÞ¦³µLAMS¯gª¬¡C

    ùþ °ª®ü©ÞªÍ¤ô¸~(high altitude pulmonary edema, HAPE)

       ·sªñ¦³®ü©Þª¦¤É¡A¥B¦³¤U¦C²{¶H¡G

       ¤@¡B¤U¦C¯gª¬¦Ü¤Ö¦³¤G¡G

           1. ¥ð®§ª¬ºA¤Uı±o©I§l§xÃø¡C

           2. «y¹Â¡C

           3. µê®zµL¤O©Î³Ò°Ê¯à¤O¤U­°¡C

           4. ¯Ý³¡ºòÁY·P©Î¥RµÈ·P¡C

       ¤G¡B¤U¦C¯f¼x¦Ü¤Ö¦³¤G¡G

           1. ¦Ü¤Ö¤@°¼ªÍ³¥¦³Åo­µ©Î­ý»ï­µ¡C

           2. ¤¤¤ß«¬µoÖæ¡C

           3. ©I§l¹L³t¡]¨C¤ÀÄÁ20¦¸¥H¤W¡^¡C

           4. ¤ß·i¹L³t¡]¨C¤ÀÄÁ90¦¸¥H¤W¡^¡C

 

°ª¤s¯gªº°ò¥»³B¸m – ¤U­°°ª«×¡B®ñ®ð¡B°ªÀ£³U

 

¡@¡@°ª¤s¯gªº³B¸m¦³©Ò¿×ªº¶Àª÷«ß¡A¹ï©ó®È«È©Mµn¤sªÌ¦Ó¨¥¡A¬O²³æ©öÀ´ªº«O©R­ì«h¡G

¡@¡@¶Àª÷«ß0¡G¡]¦³¤H¡^±o¤F°ª¤s¯f©|¤£¥²Åå·W¡A¦ý¡]Åý¶¤­û¡^¦º©ó°ª¤s¯f´N¬O

¡@¡@¡@¡@¡@¡@¡@¤£´¼¤F¡C

¡@¡@¶Àª÷«ß1¡G¦b°ª®ü©Þªº¥ô¦ó¯f¯g¡A³£À³¥ý°²©w¬O°ª¤s¯f¡Aª½¨ìÃÒ©ú¬O§Oªº¯e

¡@¡@¡@¡@¡@¡@¡@¯f¬°¤î¡C

¡@¡@¶Àª÷«ß2¡Gµ´¹ï¤£­n±aµÛAMSªº¯gª¬¤W¤É°ª«×¡C

¡@¡@¶Àª÷«ß3¡G¦pªG¯gª¬¥¿¦b´c¤Æ¡u¥ß¨è¡v¤U©¹§C®ü©Þ¡C

¡@¡@¶Àª÷«ß3¡Gµ´¹ï¤£­n±N±w¦³AMSªº¤H³æ¿W¯d¤U¡C

¡@¡@¹ï©óAMS¦Ó¨¥¡AÃĪ«¥i¯à¦³®Ä¡A¦ýµ´¹ï¤£¥i¦]¨Ï¥ÎÃĪ«¦Ó¹H­I¶Àª÷«ß¡A¯S§O¬O«É©ó¹ÎÅéÀ£¤O¡A¦æµ{§Y±N´£ª@®ü©Þ°ª«×ªº®È«È©Mµn¤sªÌ¡Cµo¥ÍAMSªº±wªÌÀ³ª`·N¨­Åé«O·x¡B´î¤Ö¬¡°Ê«×¡AºÉ¥i¯à¥Ñ¦³¸gÅ窺»â¶¤©Î¶¤¤Í³­¦PÆ[¹î¡A¸g¹L¥b¤Ñ¥H¤Wªº¥ð®§µLªk§ïµ½¯gª¬¡A©Î¦³¤´¦ó´c¤Æ¸ñ¶H¡A§YÀ³¤U­°°ª«×¡C¤@¯ë¦Ó¨¥¡A­°§C500¦Ü1,000¤½¤Ø°ª«×§Y¨¬¥H§ïµ½¤j³¡¥÷ªº¯gª¬¡C

¡@¡@HACE©MHAPE¬OÄY­«ªº«æ©Ê°ª¤s¯g¡A¦pªG¨S¦³¤U­°°ª«×¡Bµ¹®ñ®ð©Î°ªÀ£³UªvÀø¡A¦º¤`²v±Nªñ¦Ê¤À¤§¦Ê¡A¯S§O¬OHACE¡A¥i¯à¦b¨BºA¤£Ã­µo¥Í«á6-24¤p®É¤º§Y¶i®i¨ì¦º¤`¡C¨Ï¥ÎÃĪ«¤£À³¸Ó¬O©µ¿ð¤U­°°ª«×¤Î´M¨D±Ï´©®É¾÷ªºÂǤf¡C¦b¨S¦³¥æ³q¤u¨ã¥iÊï¹F¡B±Ï´©ª½ª@¾÷µLªk«e¨Óªº°ª¤s¦a°Ï¡A¶X·NÃÑ©M¦æ°Ê¯à¤O¥¼³à¥¢«e¤Î¦­ºM°h¤U­°¬O·¥¬°­«­nªº«O©R¨BÆJ¡C­Y¦a§Î¤Î¤Ñ­Ôª¬ªp¤£¤¹³\¤U­°°ª«×¡AÀ³ºÉ¥i¯à§¤µÛ¥ð®§¡Bµ¹¤©®ñ®ð¤ÎÃĪ«(¦pªG¦³ªº¸Ü)¡A¨Ã¥BÁקK±wªÌºÎµÛ¡A¥H«Ý¥~´©¡C

¡@¡@®ñ®ðªvÀø¦b°ª®ü©Þ¦a°Ï¬Û·í´¶¹M¡C¸g¥Ñ»óºÞ¡AAMS©MHACE±wªÌ§l¤J2L/min¡BHAPE±wªÌ§l¤J4L/min®ñ®ð¡A´N¯à¤j´T§ïµ½¯gª¬¡C¥@¬É¤W³\¦h¶W¹L¤T¤d¤½¤Ø°ªªº«°Âí¡A¤½¦@³õ©Ò³]¦³¤è«K¨Ï¥Îªº§l®ñ³]³Æ¡AµM¦Ó­Y¬O¥u¦³Â²©öªº®ñ®ð²~¡A¶·¯S§Oª`·N¦³­­ªº®ñ®ð¨ÑÀ³¡A¯Ê®ñª¬ºA¤@¥¹³QÁB¥¿¡A·|¶w¤Æ¥Í²z¥NÀv©Êªº°ª«×¾AÀ³¯à¤O¡A®ñ®ð¥ÎºÉ«e­Y¨S¦³¦P®É¤U­°¦Ü¸û§C®ü©Þ¡A¤´±N¦³´c¤ÆHACE©MHAPE¤§¸·¡C

¡@¡@°ªÀ£³U¬OºØ·¥¬°¦³®Äªº°ª¤s¯gªvÀø¤è¦¡¡C³q±`¤@°Æ°ªÀ£³U¦³©T©wªº®ðÀ£¼W¥[­È¡A¼ÒÀÀ®ü©Þ¤U­°1,500¦Ü2,000¤½¤ØªºªvÀø®ÄªG¡C

 

°ª¤s¯gªºÃĪ«ªvÀø

 

¡@¡@Acetazolamide(°Ó«~¤§¤@¬°Diamox)¡A¬O¹w¨¾¤ÎªvÀø°ª¤s¯gªºµÛ¦WÃĪ«¡C¥¦«P¶iµÇŦ¹ïºÒ»Ä²B®Úªº±Æªn¡A³y¦¨¥NÁ©ʻĦå¯g¥H¥[±j©I§l¤¤¼Ï¹ï¤G®ñ¤ÆºÒªº±Ó·P«×¡A¨Ó§ïµ½PAO2¡BPaO2¤ÎSaO2¡A¨Ã«P¶i°ª«×¾AÀ³¡CªvÀøAMS©ÎHACE¡A¤@¯ë¨C¤K¦Ü¤Q¤G¤p®ÉªA¥Î250mgªºacetazolamide¡C­Y¬O¹w¨¾©Ê§ëÃÄ¡A«Øij¦b¤W¤É¦Ü2,500¤½¤Ø¥H¤W°ª«×«e24¤p®É¡A¨C¹j¤Q¤G¤p®Éµ¹¤©125mgªº¾¯¶q¡Aª½¨ìÊï¹F³Ì°ª°ª«×«á48¤p®É©Î²Ä¤T­Ó±ß¤W¬°¤î¡C¹ï©ó¶g´Á©Ê©I§l³y¦¨ªº°ª®ü©Þ¥¢¯v¡A©óºÎ«e1~2¤p®ÉªA¥Î125mg¡A³Q»{¬°¬O¦w¥þ¦³®Äªº¨Ï¥Î¤è¦¡¡C¨ä°Æ§@¥Î¤£¤Ö¡A¥]¬AªÏÅé³Â¤ì·P¡Bµê®z¡Bäú¤ß¡B§C¦å¹[¡B¦h§¿¤Î¹L±Ó¡A¹ïÁDÓiÃþÃĪ«¹L±ÓªÌ¤Î¥¥°ü¬°¨Ï¥Î¸T§Ò¡C

¡@¡@Dexamethasone¹ï©ó§ïµ½AMS¯gª¬©MªvÀøHACE¦³®Ä¡A©óHAPE«hµL®Ä¥Î¡C³q±`¨C¤»¤p®Éµ¹¤©4mgªº¾¯¶q¡C­È±oª`·Nªº¬OÃþ©T¾JÃĪ«·|¦³¤Ï¼u©Ê¯gª¬¡A°±ÃÄ¥i¯à·|¥[¼@AMS©ÎHACE¯fªp¡A¬G¶·­ì®ü©ÞÆ[¹î¦Ü¤Ö18¤p®É¡AµL¤Ï¼u¯gª¬¤~¥i¥HÄ~Äò¤W¤É°ª«×¡CDexamethasone¨Ã¨S¦³«P¶i°ª«×¾AÀ³¤§®Ä¡A2008¦~¬ü°êCDC®È¹CªÌ°·±d¶À¥Ö®Ñ«Øij¦b¤W¤É°ª«×®É¨Ï¥Îacetazolamide¹w¨¾AMS¡A¦Ó«O¯ddexamethasone¦Ü¤U­°°ª«×®É¤~¨Ï¥Î¡C

¡@¡@Nifedipine(°Ó«~¦WAdalat) ¥i¦³®Ä´î¤ÖªÍ¦åºÞªý¤O¤ÎªÍ°Ê¯ßÀ£¡A¹ï¹w¨¾¤ÎªvÀøHAPE¦³®Ä¡A¹ïAMS¤ÎHACE«hµL®Ä¡C¹w¨¾©Ê¥ÎÃĬ°¨C¤Q¤G¤p®Éµ¹¤©ªø®Ä«¬20~30mgªº¾¯¶q¡AªvÀø¤wµo¥ÍªºHAPE«h¥ýµ¹µu®Ä«¬10mg¦Þ¤U¿õ¡A¤§«á¨C¤Q¤G¤p®Éµ¹¤©20~30mg¡C¨ä°Æ§@¥Î¥]¬A¦åÀ£¤U­°¤Î¤ß¸õ¥[³t¡A­YµLªk§Ô¨ü³o¼Ëªº°Æ§@¥Î¡A¥i¥H¦Ò¼{¨Ï¥Î§l¤J©Êsalmeterol¨Ó¹w¨¾©ÎªvÀøHAPE¡CSalmeterol¬Oªø®Äªºβ-¥æ·P¯«¸g§@¥Î¾¯¡A«Øij¦Û°ª«×¤W¤É«e¶}©l¨C12¤p®É§l¤@¦¸¡C

¡@¡@Sildenafil(°Ó«~¦WViagra) ¥Ñ©ó¿ï¾Ü©Ê­°§CªÍ°Ê¯ßÀ£¡A¤]³Q»{¬°¹ï¹w¨¾¤ÎªvÀøHAPE¦³®Ä¡CµM¦Ó¨Ï¥Î«e­n¦Ò¼{¨ìÀYµh¡B¼é¬õµ¥°Æ§@¥Î¡A¨ÃÁקK©Mµv»ÄÆQÃþÃĪ«¨Ö¥Î¡C

 

°ª¤s¯gªº¹w¨¾

 

¡@¡@³z¹L¹ï®È¦æ©Îµn¤s°Ï°ìªº¤F¸Ñ©M¾A·íªº¦æµ{³]­p¡A¥i¥H­°§CAMSªº¾÷²v¡A¨ÃÁקKµ´¤j¦h¼Æªº°ª®ü©Þ­«¯g—HACE¤ÎHAPEªºµo¥Í¡C½wºCª¦¤É°ª«×¡B¹w¯d¥ð®§¤é¥HÅý¨­Åé¥R¥÷¾AÀ³°ª«×¬O°ò¥»­ì«h¡A³q±`«Øij¦b®ü©Þ1,500~2,500¤½¤Ø°ª«×¥ý¦í¤@±ß¡AÊï¹F®ü©Þ3,000¤½¤Ø¥H¤W«á¡A¨C±ß¦í±J°ª«×¤£©y¤ñ«e¤@±ß°ª¥X300~600¤½¤Ø¡C¨C¹j2¦Ü3¤Ñ¡A©Î¨C¤W¤É¤@¤d¤½¤Ø¡A«Øij¥ð®§¤@¤Ñ¤£Ä~Äò¤W¤É°ª«×¡C

¡@¡@¥Ñ©ó¯Ê®ñ¯gª¬³q±`¦b©]¶¡´c¤Æ¡Aµn¤s¦æµ{©yªÃ«ù¡u¥Õ¤Ñª¦°ª¡B±ß¤WºÎ§C¡vªº­ì«h¡A¨Ã·V¿ïÁ×­·¡B«O·x¤Î®e©öºM°hªº¦í±J¦aÂI¡C¦b°ª®ü©ÞÀH®Éª`·N«O·x¡BÁקK¹L«×¼@¯P¬¡°Ê¡BÁקKªA¥Î¤¤¼Ï¯«¸g§í¨îÃĪ«¡A³£¯à¦b¬YºØµ{«×¤W´î¤Ö°ª¤s¯gªºµo¥Í¡C­Y¬O¦æµ{¦w±Æ©Î­Ó¤HÅé½è¦³¸û°ªªº°ª¤s¯g­·ÀI¡A©Î´¿¦³¥ô¦ó°ª¤s¯g¯f¥v¡A«Øij¦æ«e¦Ü®È¹CÂå¾Çªù¶E¦VÂå®v¿Ô¸ß¨Ã·Ç³Æ°ª¤s¯g¹w¨¾¥ÎÃÄ¡A¹ï©ó¦Ü«D±`°ª®ü©Þ(¶W¹L4,000¤½¤Ø)ªº®È¦æªÌ¦Ó¨¥¡A®ñ®ð©Î°ªÀ£³U¬O¥i¥H¦Ò¼{ªº°t³Æ¡C

¡@¡@¦b¹Î¶¤¤¬°Ê¤W¡A¦P¤@¹ÎÅ骺®È¦æªÌ©Îµn¤s«ÈÀ³©¼¦¹·ÓÀ³¡A¤¬¬ÛÃö¤ß®e©ö³Q©¿²¤©Î»~»{¬O¨ä¥¦»´¯gªº¯gª¬¡A¦h¤@¤Àĵı¡A±N¤Ö¤@¤À¦]°ª¤s¯g³y¦¨ªºµL¥i®¾¦^ªº«áªG¡C

 

¡@¡@¯¸¦b®È¹CÂå¾Ç¤Î¹w¨¾Âå¾ÇªºÆ[ÂI¡A°ª¤s¯g¬O¥i¥H¿n·¥¹w¨¾¡B¦³®ÄªvÀøªº¯e¯f¡CÀHµÛ¶V¦h¶V¦hÃö©ó­P¯f¾÷Â઺¬ã¨s©MªvÀø¤è¦¡ªº¶i®i¡AÄY­«°ª¤s¯gªºµo¥Í¤£¦A¨º»ò¥O¤H¤â¨¬µL±¹¡A¥u­n°ª®ü©Þ®È¦æªÌ³£¯à¨Æ¥ý°µ¦n©P¸Ôªº®È¦æ©Îµn¤s­pµe¡A¥²­n®É³z¹L®È¹CÂå¾Ç©Î®a®xÂå¾Ç¬ìÂå®vªº¨ó§U«ü¾É¡A±N¯àÁקK¿ò¾Ñµo¥Í¡A´r§Ö±u«â°ª¤s®mÀ­ªº¬üÄR¤sªL¡AÂ×´Iµø¬É»P¤H¥Í¡C

 

°Ñ¦Ò¸ê®Æ¡G

  1. Centers for Disease Control and Prevention, USA (2008)

 Altitude Illness in Health Information for International Travel, USA

  1. °ª°¶®p. °ª¤s¯gHigh Altitude Syndrome. ®È¹CÂå¾Ç°V½m¤â¥U(¥Á96).
  2. °ª°¶§g, ´¿¬K¨å, ³¯¨qº³, °¨´f©ú, ³¯«T©¾, °ª°¶®p¡C

   ¥H¥É¤sµn¤s¤f»P¥­¦a¦å®ñ¹¡©M«×®t²§¹w´ú«æ©Ê°ª¤s¯f¡C¤¤µØ¥Á°ê«æ±Ï¥[Å@Âå¾Ç·|Âø»x¡A17¨÷2´Á¡F47-54¡C

  1. °ª°¶®p, ³¢­^½Õ¡B³¢«Ø¤¤µ¥¡C1999¦XÅw¤s³·©u°ª¤s¯g¤Îºò«æÂåÀø±ÏÅ@±´°Q¡C¤¤µØ¥Á°ê«æ¶EÂå¾Ç·|Âø»x¡C2(1): 34-45.
  2. P W Berry, A J Pollard. Altitude Illness. BMJ 2003;326:915~919.
  3. Michael P.W. Grocott, M.B., B.S., et al. Arterial Blood Gases and Oxygen Content in Climbers on Mount Everest. N Eng J Med, 360;2:140-149 Jan.8, 2009
  4. Dante Penaloza, MD; Javier Arias-Stella, MD, FRCP. Healthy Highlanders and Chronic Mountain Sickness, Circulation 2007; 115:1132-1146.
  5. Buddha Basnyat, David R Murdoch. High-altitude illness.  Lancet. 2003;361:1967-1974.
  6. George W. Rodway, MSN, CRNP, et al. High-altitude-related disorders. Heart & Lung Vol. 32, No.6:353~359; Vol. 33, No.1:3~12.